Why First Tracks Biotherapeutics, Inc.’s (TRAX) Stock Is Down 6.77%
As of Thursday, November 12, First Tracks Biotherapeutics, Inc.’s TRAX share price has dipped by 6.77%, which has investors questioning if this is right time to buy.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jenna Brashear
Jenna Brashear
Michael Rose
Cynthia McLaughlin
| Share Statistics | TRAX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,826.9 | $208.2 | 54% |
|
| Shares Out (Mil) | 35.7 | 55.4 | 40% |
|
| Institutional Ownership | 98.2% | 92.9% | 77% |
|
| Float (Mil) | 34.5 | 40.7 | 38% |
|
| Beta | na | 1.00 | na |
|
| Avg Daily Volume (000s) | 635 | 570 | 60% |
|
| Price Change (52-week) |
na | 40.7% | na |
|
| Growth | TRAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.3%) | na |
|
| EPS (5yr) | na | 15.5% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 10 | 11 | |
| Current EPS | ($0.702) | ($3.868) | ($3.463) | |
| Month Ago EPS | ($0.819) | ($4.029) | ($3.622) | |
| # Rev Up | 3 | 0 | 1 | |
| # Rev Down | 3 | 1 | 1 | |
| Three Months Ago EPS | ($0.826) | ($4.062) | ($3.665) | |
| Year/Year Chg | (20.0%) | na | na | |
| Financials | TRAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($150) | ($44) | 8% |
|
| EPS (TTM) | ($4.172) | ($1.400) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($110) | ($34) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($17) | $-0 | 29% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 18% |
|
| Enterprise Value (Q1) (Mil) | $1,757 | $138 | 48% |
|
| Valuation | TRAX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.33 | 1.96 | 92% |
|
| P/E | na | 17.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | TRAX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (175.8%) | (47.4%) | 2% |
|
| ROE | (198.4%) | (51.6%) | 4% |
|
| Liabilities to Assets | 11.4% | 29.7% | 7% |
|
| F-Score | 1 | 3 | na |
|
First Tracks Biotherapeutics, Inc. did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors